glp 1 cardiovascular effects Figure from of Glucagon-Like Peptide-1 Receptor Agonists GLP-1 Agonists in Cardiovascular Diseases:

The syringe isn't just a delivery device

Oxidation kinetics for roGFP2 WT -PfGrx fusion constructs The in vivo oxidation kinetics from fusion constructs between roGFP2 WT and a variety of glutaredoxins and mutants thereof were shown to correlate very well with the rate constants for the oxidative half-reaction from GSSCys assays in vitro, suggesting that the glutathionylation of the glutaredoxin and not the transfer of oxidation to the fused roGFP2 moiety was rate-limiting under the chosen conditions 15,34,35

A very recently reported synthetic, antibacterial molecule MTEBT-3 has also been shown to inhibit P

doi:10.1001/jamacardio.2020.7073 Muscella A, Stefno E, Marsigliante S